Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/9/2017 |
| Start Date: | April 11, 2005 |
| End Date: | November 1, 2006 |
A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer
This Study was designed to determine how effective and safe a new investigational drug,
lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed
inflammatory breast cancer. Tumor tissue collected pre-treatment, following 14 days of
treatment and at the time of surgical resection will be examined for pathologic response and
biologic activity by IHC (immunohistochemistry) within the tumor. Treatment will consist of
14 days of lapatinib monotherapy followed by 12 weeks of combination therapy with lapatinib
and paclitaxel. Blood samples for hematology and chemistry panels, MUGA/ECHO exams and
physical exams will be performed throughout the study to monitor safety.
lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed
inflammatory breast cancer. Tumor tissue collected pre-treatment, following 14 days of
treatment and at the time of surgical resection will be examined for pathologic response and
biologic activity by IHC (immunohistochemistry) within the tumor. Treatment will consist of
14 days of lapatinib monotherapy followed by 12 weeks of combination therapy with lapatinib
and paclitaxel. Blood samples for hematology and chemistry panels, MUGA/ECHO exams and
physical exams will be performed throughout the study to monitor safety.
Inclusion criteria:
- Tumor accessible for multiple biopsies
- ECOG (Eastern Cooperative Oncology Group) performance status 0-2
- Adequate bone marrow
- Renal and hepatic function
- LVEF (left ventricular ejection fraction) greater than 0% based on ECHO
(echocardiogram) or MUGA (multigated acquisition).
Exclusion criteria:
- Females who are pregnant or nursing.
- Any unstable, pre-existing major medical condition.
- Received an investigational drug within the past 4 weeks.
- Had major surgery in the past 2 weeks.
- Currently receiving amiodarone or has received amiodarone in the past 6 months.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials